Pharma BD Deal Intelligence

Bristol Myers Squibb / Chai Discovery, Inc.

2026 · Co-Development · Complete

Chai Discovery and Bristol Myers Squibb entered a collaboration under which BMS will apply Chai's AI molecular folding and design models to discover therapeutic antibody candidates across its portfolio, supporting BMS's build-out of an AI-powered discovery system. Financial terms were not disclosed. The agreement extends Chai's existing pharma partnerships, which already include Eli Lilly, Pfizer and Novartis.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals